About Dr. Shen Ce
Dr. Shen Ce (沈策) is Chief Physician, Professor, and one of China's foremost authorities on tuberculosis (TB) and drug-resistant tuberculosis at Shanghai Pulmonary Hospital, Tongji University School of Medicine — China's largest and most specialized pulmonary disease center and the national reference institution for TB diagnosis and treatment. With decades of clinical experience managing the full spectrum of TB disease — from drug-sensitive pulmonary TB to extensively drug-resistant (XDR-TB) and treatment-refractory cases — Dr. Shen is among the most experienced TB clinicians in Asia.
Dr. Shen's clinical program is built around individualized, regimen-optimized treatment for every TB patient. For patients with drug-sensitive TB, this means ensuring the most effective standard regimen is correctly administered and monitored. For patients with multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB) — conditions that require complex, prolonged, and carefully managed treatment regimens — Dr. Shen's expertise in drug susceptibility testing interpretation, newer anti-TB agents (bedaquiline, delamanid, pretomanid), and individualized regimen construction is unmatched in China. His department manages one of the highest volumes of MDR/XDR-TB cases in the country, with outcomes that reflect both clinical expertise and institutional infrastructure.
Dr. Shen is also a recognized expert in extrapulmonary TB — including TB meningitis, spinal TB (Pott's disease), TB lymphadenitis, pleural TB, and abdominal TB — conditions that are frequently misdiagnosed or inadequately treated outside specialized centers. His multidisciplinary approach integrates pulmonology, infectious disease, radiology, microbiology, and surgery to ensure comprehensive management of complex TB presentations.
Hospital Affiliation: Shanghai Pulmonary Hospital
Shanghai Pulmonary Hospital (同济大学附属上海市肺科医院) is China's largest and most specialized pulmonary disease center, affiliated with Tongji University School of Medicine. It is the national reference institution for tuberculosis, with a dedicated TB ward, a WHO-recognized TB laboratory, and a clinical program that manages thousands of TB cases annually — including a disproportionately high volume of MDR-TB and XDR-TB referrals from across China and internationally.
The hospital's TB laboratory is equipped for rapid molecular diagnostics including GeneXpert MTB/RIF, line probe assays (LPA), whole-genome sequencing (WGS) for comprehensive drug resistance profiling, and culture-based drug susceptibility testing (DST) for both first-line and second-line anti-TB drugs. This diagnostic infrastructure enables precise characterization of drug resistance patterns and supports the construction of individualized treatment regimens for the most complex cases.
Clinical Expertise
- Drug-sensitive pulmonary TB — standard HRZE regimens; treatment optimization for patients with comorbidities (diabetes, HIV, liver disease, renal impairment); management of adverse drug reactions; treatment monitoring and outcome assessment
- Multidrug-resistant TB (MDR-TB) — individualized regimen construction based on comprehensive DST; WHO Group A/B/C drug selection; bedaquiline-containing regimens; shorter MDR-TB treatment regimens (BPaL, BPaLM); treatment monitoring and toxicity management
- Extensively drug-resistant TB (XDR-TB) — regimen design for pre-XDR and XDR-TB; bedaquiline, delamanid, pretomanid combinations; compassionate use access for novel agents; long-term treatment monitoring
- Extrapulmonary TB — TB meningitis; spinal TB (Pott's disease) with neurosurgical coordination; TB lymphadenitis; pleural TB and empyema; abdominal TB; pericardial TB; genitourinary TB
- TB in special populations — TB/HIV co-infection; TB in immunocompromised patients (transplant recipients, biologics users, corticosteroid-dependent patients); TB in pregnancy; pediatric TB; elderly patients with TB
- Latent TB infection (LTBI) — IGRA and TST interpretation; LTBI treatment for high-risk individuals; pre-biologic and pre-transplant TB screening and management
- Treatment-refractory and relapsed TB — salvage regimen design; surgical referral coordination for cavitary or destroyed lung disease; management of post-TB lung sequelae
- Molecular diagnostics — GeneXpert MTB/RIF; whole-genome sequencing for resistance profiling; interpretation of complex resistance patterns
Academic Leadership & Research Contributions
Dr. Shen Ce has made substantial contributions to TB research in China, with publications in leading infectious disease and pulmonology journals covering MDR-TB treatment outcomes, novel anti-TB drug regimens, and the epidemiology of drug-resistant TB in China. His research has informed national TB treatment guidelines and contributed to the evidence base for the use of newer anti-TB agents in China's clinical practice.
He is an active participant in national and international TB research networks and has collaborated with WHO, the Global Fund, and international TB research consortia on studies of MDR-TB treatment optimization. His clinical expertise is regularly sought for complex case consultations from hospitals across China and from international clinicians managing patients with TB acquired in China or seeking treatment in Shanghai.
Dr. Shen contributes to the training of infectious disease and pulmonology specialists at Shanghai Pulmonary Hospital and Tongji University, and has been involved in the development of clinical protocols for MDR-TB management that are used as reference standards across China.
Why International Patients Choose Dr. Shen Ce
For international patients with tuberculosis — particularly those with drug-resistant TB, treatment failure, or complex extrapulmonary presentations — Dr. Shen's program at Shanghai Pulmonary Hospital offers a level of diagnostic precision and treatment expertise that is genuinely rare outside of a small number of global reference centers. The combination of Shanghai Pulmonary Hospital's molecular diagnostic infrastructure, its access to newer anti-TB agents (including bedaquiline and delamanid, which may not be available or accessible in the patient's home country), and Dr. Shen's personal expertise in regimen construction for the most resistant cases makes this program a genuine option of last resort for patients who have not responded to treatment elsewhere.
For patients from countries with high TB burden who are seeking care in China, or for expatriates and international travelers who have developed TB while in China, Dr. Shen's program provides a clear pathway to accurate diagnosis, appropriate drug susceptibility testing, and optimized treatment. CMCS has coordinated TB consultations and treatment programs for patients from Southeast Asia, Central Asia, Africa, and Eastern Europe through Dr. Shen's department.
Treatment costs at Shanghai Pulmonary Hospital are substantially lower than equivalent TB care in Western healthcare systems, and the hospital's experience with international patients — including documentation, reporting, and coordination with home country health authorities — is well established.
What to Expect at Your Consultation
Consultations with Dr. Shen begin with a comprehensive review of all prior microbiological results (sputum smear, culture, GeneXpert, DST), imaging studies (chest CT, MRI for extrapulmonary disease), treatment history (all prior anti-TB regimens, durations, and outcomes), and relevant comorbidity information. CMCS will arrange certified translation of all medical records in advance.
Dr. Shen will assess whether additional diagnostic workup is needed (repeat culture, molecular resistance profiling, WGS), outline the recommended treatment regimen with rationale, discuss the expected treatment duration and monitoring schedule, and address any concerns about drug availability, adverse effects, or treatment logistics. For patients with MDR-TB or XDR-TB, a detailed written treatment plan is provided, which can be shared with the patient's home country TB program or infectious disease physician to facilitate coordinated care.
A written English-language consultation summary is provided after every appointment, documenting the diagnosis, resistance profile, recommended regimen, and follow-up plan.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking TB consultation and treatment with Dr. Shen Ce at Shanghai Pulmonary Hospital. Our services include priority consultation scheduling, certified medical record translation, pre-consultation microbiological and imaging review, treatment logistics and pharmacy coordination, on-site interpretation, and ongoing follow-up coordination between Dr. Shen's team and the patient's home physician or TB program.
댓글 0개